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Abstract 
The aim of this prospective study was to evaluate the clinical response of dogs with cutaneous lymphoma treated with 
lomustine (CCNU) and to identify possible adverse effects and toxicity during treatment. Fifteen dogs, seven females and eight 
males aged between five and 17 years old, diagnosed with cutaneous lymphoma by histopathological analysis were selected and 
treated with lomustine at 90 mg/m² every three weeks. Monitoring was carried out and consisted of the assessment of 
laboratory hematology and serum chemistry before and during treatment. Partial response was observed in 53.3% of the 
animals. None of the animals achieved a complete response and seven dogs (46.6%) had progressive disease. The median 
survival time was 22 days. The major hematological and biochemical changes found after therapy were leukopenia (73.3%), 
thrombocytopenia (60%) and anemia (46.1%). Renal and liver toxicity was observed in 40% and 73.3% of dogs, respectively. 
Hematocrit, total protein, leukocyte count, neutrophil count, serum creatinine, ALT, GGT, alkaline phosphatase and urine 
specific gravity were affected during therapy. The use of lomustine as a monotherapy in the treatment of canine cutaneous 
lymphoma was effective; however, adverse effects occurred and compromised the quality of life of the majority of dogs in this 
study. Therefore, lower doses of lomustine should be considered in future studies.  
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Resumo 
O objetivo deste estudo prospectivo foi avaliar a resposta clínica de cães com linfoma cutâneo tratados com lomustina 
(CCNU) e identificar possíveis efeitos adversos e toxicidade durante o tratamento. Quinze cães, sendo 7 fêmeas e 8 machos, 
com idades entre 5 e 17 anos diagnosticados com linfoma cutâneo por avaliação histopatológica foram selecionados e tratados 
com lomustina na dose de 90 mg/m2 a cada três semanas. Os cães foram monitorados por avaliação hematológica e 
bioquímica sérica antes e durante o tratamento. A resposta parcial foi observada em 53,3% dos animais. Nenhum dos animais 
apresentou resposta completa e sete animais (46,6%) apresentaram progressão da doença. O tempo médio de sobrevida foi de 
22 dias. As principais alterações hematológicas e bioquímicas observadas após o tratamento foram leucopenia (73,3%), 
trombocitopenia (60%) e anemia (46,1%). Sinais de toxicidade renal e hepática foram observados em 40% e 73,3% dos cães, 
respectivamente. Durante o tratamento foram afetados os parâmetros hematócrito, proteínas séricas totais, contagem de 
leucócitos, contagem de neutrófilos, creatinina sérica, ALT, GGT, fosfatase alcalina e densidade urinária. O uso de lomustina 
como monoterapia no tratamento do linfoma cutâneo canino foi efetivo; entretanto, efeitos adversos ocorreram e 
comprometeram a qualidade de vida da maioria dos animais neste estudo. Assim, sugere-se que doses mais baixas de 
lomustina sejam consideradas em estudos futuros.  
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Introduction 
Skin is considered the most common site for the 
onset of tumors in dogs, representing approximately 
1/3 of all cases of neoplasms in this species (HAUCK, 
2013). 
Cutaneous lymphoma (CL) is considered a rare 
form of canine lymphoma, representing only 1% of 
canine neoplasms in dogs (FONTAINE et al., 2009). It 
is characterized by T or B neoplastic lymph cells 
proliferation and infiltration in the epidermis, dermis 
and cutaneous annexes (FONTAINE et al., 2010).  
Although its etiology is unknown, cutaneous 
lymphoma has been associated with chemical 
compounds, viral infections and chronic skin 
inflammation (MOORE; OLIVRY, 1994; FOURNEL-
FLEURY et al., 2002; FONTAINE et al., 2009) and it 
occurs more frequently in elder dogs (average nine to 
10 years-old), with no predilection for gender 
(MOORE; OLIVRY, 1994). According to the 
literature, there is a predisposition in Cocker Spaniels 
and Boxers (FONTAINE et al., 2009). 
Canine cutaneous lymphoma represents a group of 
heterogeneous clinical presentations that may be 
histologically classified as cutaneous epitheliotropic 
lymphoma (CEL) and non-epitheliotropic lymphoma 
(NEL), with the CEL type being more frequently 
described in veterinary medicine. The main clinical 
signs are: exfoliative erythema, plaques, nodules, 
ulceration of oral mucosa and the mucocutaneous 
form (FONTAINE et al., 2009). An important 
variability on clinical behavior of the disease is 
observed – from an indolent clinical course to a 
rapidly fatal systemic disease, with three to six 
months’ survival time for the advanced disease 
(HEADING et al., 2011). In most cases, cutaneous 
lymphoma is diagnosed in advanced stages, with 
multifocal lesions and dissemination to other organs, 
making systemic chemotherapy more suitable 
(LORIMIER, 2006).  
The use of lomustine chemotherapy (CCNU), an 
alkylating agent of the nitrosurea class, has been 
reported in several neoplasms such as cerebral 
tumors, mast cell tumors, relapsing lymphoma and 
histiocytic sarcoma (HEADING et al., 2011). Its use 
alone or in combination with other chemotherapeutic 
drugs in cases of canine cutaneous lymphoma has 
been widely studied, both on initial approach and on 
relapsing cases. Willians et al. (2006) and Risbon et al. 
(2006) reported more than 70% of therapeutic 
response with the use of CCNU in cases of cutaneous 
lymphoma in dogs. Satisfactory results associated 
with a relative low cost and practical administration 
make lomustine a promising therapeutic choice. On 
the other hand, the toxicological potential of this drug 
has been evaluated and its use has been associated 
with side effects. Myelosuppression is the most 
frequent side effect, followed by gastrointestinal signs 
(KRISTAL et al., 2004; HEADING et al., 2011). 
Nephrotoxicity and hepatotoxicity are also described, 
shortening the survival length of treated animals.  
The aims of the present study were to characterize 
the canine population diagnosed with cutaneous 
lymphoma, to evaluate the therapeutic response with 
lomustine therapy; and to describe the side effects 
associated with this chemotherapeutic agent. Also, the 
authors tried to establish any clinical or laboratorial 
parameters that could be correlated with prognosis.  
 
Material and Methods 
The dogs were selected among cases attended at 
the Veterinary Hospital at São Paulo State University 
in Botucatu and all the owners signed a consent form 
before having their animals treated with lomustine. 
Dogs were eligible for inclusion in the study if they 
had a histopathological diagnosis of cutaneous 
lymphoma. Exclusion criteria included patients 
treated concurrently with other chemotherapy drugs 
or corticosteroids while on lomustine therapy, and 
insufficient patient follow-up.  
After the confirmation of the diagnosis, therapy 
with lomustine (Citostal®, Bristol) at 90 mg/m2 PO, as 
well as the clinical evaluation, was initiated and 
repeated every three weeks, except when the animals 
presented with the total white blood cell count less 
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than 3,000/µL and/or with platelet count less than 
50,000/µL.  
All the animals were monitored for the evolution 
of therapy, both during induction of remission and 
maintenance. Clinical follow-up was based on 
macroscopic evaluation of the lesions. According to 
the size of the nodules, therapy response was 
determined by the following criteria: 1) stable disease 
(SD – 0% tumor decrease); 2) partial remission (PR – 
50% tumor decrease); 3) complete remission (CR – 
100% tumor decrease); and 4) progressive disease 
(further tumor increase). 
Toxicosis associated with lomustine therapy was 
graded according to the Veterinary Cooperative 
Oncology Group Common Terminology Criteria for 
Adverse Events criteria (VETERINARY, 2011). 
Laboratory follow-up was done before the beginning 
of therapy and during the whole course of 
chemotherapy treatment. It consisted in monitoring 
the complete blood count (red blood cells, white 
blood cells and platelets), serum biochemistry (urea, 
creatinine, ALT, ALP, GGT, total protein, albumin, 
globulin) and urinary parameters (density, pH and 
protein). The reference values used were those 
proposed by Kaneko et al. (2008). Additional tests, 
such as thoracic x-rays and abdominal ultrasound, 
were performed to prove that the lymphoma was only 
confined to the skin. Immunohistochemistry was 
performed in all tumor samples. All animals were 
diagnosed with T-cell cutaneous lymphoma.  
All clinical and laboratory parameters were 
assessed on Day 1, the first day of treatment (M1) and 
before each administration of chemotherapy, every 
three weeks. The degree of increase or decrease of the 
evaluated parameters (hematology, serum 
biochemistry and urinalysis) was based on the highest 
or lowest recorded change (M2). According to each 
animal’s particular needs, additional laboratory tests 
were performed when deemed indicated by the 
clinician’s discretion. 
Based on data collected at the initial examination 
of all animals, Shapiro-Wilk normality test was 
applied and demonstrated that the parameters are not 
normally distributed. For this reason, statistical 
analysis was based on non-parametric methods. To 
check the influence of the treatment on several 
parameters evaluated, Mood Median Test was used 
and 95% of significance was adopted. Pearson test was 
used to evaluate the correlation between 
hematological, biochemical and urinary parameters 
and survival time. For this test, a critical value of 
0.514 was adopted. The relationship between the 
probability of survival and time was verified by 
Kaplan-Meier test, and 95% significance was adopted. 
 
Results and Discussion 
For the present study, 15 dogs with cutaneous 
lymphoma were selected. Of these, 53.3% (8/15) were 
mongrel dogs and 46.7% (7/15) were from different 
breeds 14.3% (1/7) for each of the following breeds: 
Border Collie, Boxer, Dalmatian, Labrador Retriever, 
Lhasa Apso, American Pit Bull Terrier and Poodle. 
Among those breeds, only the Boxer was previously 
described as predisposed to canine lymphoma. 
However, evaluation of racial predisposition is 
debatable, since the reported cases of cutaneous 
lymphoma come from many different countries and 
regions, and in most cases, the distribution of breeds 
in each place is not known (FONTAINE et al., 2009). 
The mean age at diagnosis in the present study was 
10.7 ± 4 years, while the median was 8.9 years, and as 
for gender, 53.3% were males and 47.7% females. In a 
total of 72 previously reported cases, the mean age at 
the moment of diagnosis was 8.6 years (FONTAINE 
et al., 2009), which demonstrates that dogs affected by 
cutaneous lymphoma are middle aged and older. 
Regarding the histopathological evaluation, 13 
samples were classified as non-epitheliotropic 
cutaneous lymphoma (NEL) and two as cutaneous 
epitheliotropic lymphoma (CEL). The CEL type is 
reported to be the most common form of cutaneous 
lymphoma in dogs (MOORE; OLIVRY, 1994); 
however, in the present study, the NEL type was 
predominant, representing 86.6% (13/15) of evaluated 
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animals. The high incidence of NEL may be due to a 
limited number of cases found in our study. 
Among the cases included in this study, 53.3% 
(8/15) of the animals responded to lomustine therapy 
with partial remissions, there were no complete 
remissions, and seven (46.6%) dogs had progressive 
disease. The assessment of therapeutic response in 
cutaneous lymphoma can be quite subjective, because 
since all the animals had diffusely distributed lesions, 
analysis of each one of the lesions may become 
impossible. However, the clinical improvement or 
reduction of pre-existing lesions were considered a 
parameter to evaluate the response to treatment. 
The mean cumulative dose of CCNU 
chemotherapy was 204 mg/m2 and average number of 
cycles required for clinical remission was two cycles, 
ranging from one to five cycles.  
The overall rate of response to treatment was 
53.3%, lower than those described by Willians et al. 
(2006) and Risbon et al. (2006), using CCNU 
60mg/m2 every three weeks (78% and 80%, 
respectively). Although a direct comparison with 
historical studies could not be made, the lower 
response to therapy noted in the present study should 
be considered carefully because, in those studies, there 
was previous sensitization or combination with other 
antineoplastic agents, such as glucocorticoids, which 
are known for leading to initial disease remission. 
According to the results provided by Kaplan-Meier 
test (Figure 1), the median survival time, representing 
50% of the studied population, was 22 days, which is 
lower than that reported by Willians et al. (2006). The 
short survival time of our population of dogs may be 
related to the late diagnosis of the disease. These 
animals had already gone through previous 
unsuccessful skin treatments and presented a more 
advanced clinical stage, an aspect not pointed out on 
studied reports. 
The predominance of dogs with non-
epitheliotropic cutaneous lymphoma may also explain 
the shorter survival time and lower rate of therapeutic 
response in this study, since in studies conducted by 
 
Figure 1 – Kaplan-Meier curve for probability of survival 
versus survival time (days) of dogs with 
cutaneous lymphoma treated with lomustine.  
 
Risbon et al. (2006) and Willians et al. (2006) all dogs 
had epitheliotropic cutaneous lymphoma. This 
difference may suggest that the type of cutaneous 
lymphoma could influence the therapeutic response 
and that the NEL type may be associated with a worse 
prognosis when compared to the CEL type. 
The use of lomustine can lead to different 
presentations of toxicity. The first indication of 
toxicity observed when a dose of 90 mg/m2 is used is 
myelosuppression, especially neutropenia, seven days 
after the administration of the drug (KRISTAL et al., 
2004; RISBON et al., 2006). It is known that 
lomustine, like other chemotherapeutic agents, acts 
by destroying cells in a nonspecific manner, both 
neoplastic and normal cells, in particular fast-growing 
cells, such as gastrointestinal and immune system 
cells (ALMEIDA et al., 2005). Ninety-three percent 
(14/15) of the evaluated animals showed a reduction 
in the WBC count (especially neutropenia) from M1 
to M2. Twenty-six percent of the animals (4/15) 
presented significant leukopenia (mean 465 cells/uL, 
VCOG-CTCAE grade 4); 26% (4/15) presented 
moderate leukopenia (mean 1,662 cells/uL, VCOG- 
CTCAE grade 1) and 20% (3/15) presented mild 
leukopenia (mean 4,700 cells/uL, VCOG-CTCAE 
grade 1) at end of chemotherapy. One animal showed 
a decreased total leukocyte count, but remained 
within the reference range. Although leukopenia 
makes the animals highly susceptible to infections and 
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sepsis, no fever or other clinical signs of sepsis were 
observed in the evaluated animals. 
Nonregenerative anemia was detected in 86.6% 
(13/15) of studied dogs; 53.8% (7/15) were diagnosed 
with nonregenerative anemia before chemotherapy 
and 46.1% (6/15) after treatment with lomustine. 
Mean values of hemoglobin and hematocrit at the end 
of chemotherapy were 9.4 g/dl (VCOG-CTCAE grade 
2) and 27% (VCOG-CTCAE grade 2) respectively, 
indicating anemia. However, blood transfusion was 
not necessary in any individual case. 
Thrombocytopenia was detected in 60% (9/15) of 
cases after the administration of lomustine. Mean 
platelet count at M2 was 154,062 platelets/uL (VCOG-
CTCAE grade 1), evidencing thrombocytopenia, 
although hemorrhagic episodes were not observed. 
Myelosuppression observed in this study was quite 
evident after several sessions of chemotherapy, 
suggesting a cumulative toxicity of lomustine in these 
animals. This may be reversed or alleviated by 
reducing the dose of the chemotherapeutic agent and 
providing appropriate supportive treatment. Rassnick 
et al. (1999) evaluated the effects of lomustine in dogs 
with mast cell tumors and reported that 41% (7/17) of 
the evaluated animals developed leukopenia (< 1000 
total leukocytes VCOG-CTCAE grade 3-4), but only a 
few showed signs of systemic infection. 
Gastrointestinal toxicity was an important finding 
in 60% of dogs. Anorexia (VCOG-CTCAE grade 2) 
was the clinical sign most frequently described by the 
owners (83.3%), followed by vomiting (16.6%, VCOG-
CTCAE grade 1) and diarrhea (8.3%, VCOG-CTCAE 
grade 2). Anorexia is a nonspecific common clinical 
symptom in cancer patients, probably associated with 
a natural process of the disease and anorexigenic 
substances produced by the tumor or by the body 
itself in response to the neoplastic process (SILVIA, 
2006). Nevertheless, since the clinical signs were only 
observed after the administration of lomustine, we 
may conclude that anorexia in these cases probably 
was not associated with a paraneoplastic syndrome. 
Hepatotoxicity caused by the use of lomustine is 
recognized by increased serum liver enzymes, 
especially ALT and hypoalbuminemia (KRISTAL et 
al., 2004). When values obtained in serum 
biochemistry at M2 were compared to those obtained 
at M1, 93.3% (14/15) of evaluated animals presented 
increased levels of ALT (VCOG-CTCAE grade 2), 
86.6% (13/15) presented increased levels of ALP 
(VCOG-CTCAE grade 1), and 33.3% (5/15) presented 
increased levels of GGT (VCOG-CTCAE not 
determined). These three parameters were 
significantly different between moments (table 1). 
This finding supports the results obtained by Kristal 
et al. (2004) and Hosoya et al. (2009) that the use of 
CCNU can lead to hepatocellular injury and 
cholestasis. 
Hosoya et al. (2009) observed in their study that 
one of the animals presenting clinical liver disease did 
not present increased levels of ALT, suggesting that 
this parameter should not be assessed in isolation as a 
marker of hepatotoxicity but in conjunction with 
other biochemical analyzes, such as the determination 
of bile acids and bilirubin. In the present study, no 
animal showed clinical signs of active liver disease or 
liver failure; however, recent studies evaluating the 
toxicity of lomustine reported the occurrence of liver 
failure and death in 1.2% (HEADING et al., 2011) to 
4.0% of patients (KRISTAL et al., 2004). We suggest 
that the outcome of liver evaluation may consider a 
subclinical hepatotoxicity in these animals and that 
critical monitoring may be required. Concurrent use 
of an association of Silymarin and S-
adenosylmethionine to minimize increased liver 
enzyme activity in dogs receiving CCNU is supported 
by the study of Skorupski et al. (2011). 
Evidences of renal toxicity, such as azotemia, 
polyuria, and polydipsia, are also reported, but 
usually to a lesser degree (HEADING et al., 2011; 
FLORY et al., 2008). In this study, although there 
were no complaints of clinical symptoms related to 
renal failure, increased values of urea (VCOG-CTCAE 
grade 1) and creatinine (VCOG-CTCAE grade 2) were 
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observed in 66.6% (10/15) and 40% (6/15) of the 
evaluated animals at M2, respectively. Urinary density 
was also evaluated during therapy and was decreased 
(VCOG-CTCAE not determined) in 93.3% (14/15) of 
the animals, reaching isosthenuria in two cases. All 
animals exhibited proteinuria and 53.3% (8/15) of the 
animals presented values of urinary protein above 100 
mg/dl; cellularity was observed in two of those 
animals (25%), which may have influenced the 
interpretation of the urinary protein levels. According 
to Polzini (2007), proteinuria may be present in the 
initial stage of renal disease, even before the 
development of azotemia. These results evidenced the 
nephrotoxic potential of lomustine therapy, with 
decreased urinary density, which is known to be the 
first clinical evidence of renal tubular injury. In 
association with decreased urinary density, persistent 
proteinuria was also verified; this parameter is 
considered an indicator of glomerular injury and its 




Table 1 – Median values for hematologic, biochemical and urinary parameters of 15 dogs with canine 
cutaneous lymphoma, obtained before (M1) and after (M2) chemotherapy with lomustine – 
Botucatu, SP – 2012 
Parameters M1 M2 P value 
Red Blood Cells (106/µL) 5.51a 3.83b 0.049 
Hemoglobin (g/dL) 12.95a 9.4b 0.007 
Hematocrit (%) 38.5a 27b 0.023 
Total Protein (g/dL) 8.2a 6.7b 0.021 
Platelets (/µL) 154000 154062 1 
White blood cells (/µL) 9300a 1890b 0.002 
Bands (/µL) 0 0 0.345 
Segmented (/µL) 5450a 2300b 0.018 
Lymphocytes (/µL) 600 210 0.431 
Eosinophils (/µL) 300 0 0.224 
Basophils (/µL) 0 0 0.172 
Monocytes (/µL) 550 250 0.431 
Urea (mg/dL) 39.5 79 0.023 
Creatinine (mg/dL) 0.90 1.55 0.058 
ALT (UI/L) 54a 242.05b 0.00015 
ALP (UI/L) 108.5a 381.95b 0.023 
GGT (UI/L) 3a 6.15b 0.002 
Albumin (g/dL) 2.3 2.1 0.058 
Globulin (g/dL) 5.7 4.9 0.130 
Urinary Density 1026a 1015b 0.00013 
Urinary pH 6.5 6.35 0.308 
Urinary protein (mg/dL) 30 100 0.053 
ab Different letters in a row indicate significant difference (P ????? 
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Significant differences in serum levels of urea and 
urine density were observed between M1 and M2, 
thus suggesting the potential deleterious effects of the 
use of lomustine in the evaluated dogs (Table 1). An 
important fact to consider is that some of these 
animals had become anorexic, with episodes of 
vomiting and diarrhea during chemotherapy, and this 
may have led to the development of dehydration and 
pre-renal azotemia leading to an increase in urine 
density, especially in the first urine of the day. 
However, these clinical aspects were not consistent 
with alterations in urine density.  
The risk of toxicity influences the dosage and 
frequency of administration of lomustine. Previous 
studies suggest that the adverse effects of CCNU are 
dose-dependent, so its use at lower doses would 
induce fewer side effects and greater reversibility of 
clinical signs (KRISTAL et al., 2004). Risbon et al. 
(2006) used lower dosages than that used in the 
present study (overall median starting dose of 60 
mg/m²) and obtained higher rates of response to 
treatment (82.6%). This indicates that higher doses 
may not achieve the desired cytotoxic effect since 
many dogs need to have their lomustine treatment 
postponed due abnormalities encountered in the 
bloodwork. Higher doses may also cause even more 
injury or shorten the animals' lifetime. Because 
lomustine is offered in pills and, thus, is an outpatient 
drug, it may be erroneously assumed that CCNU is 
not as harmful as other chemotherapy agents and, 
therefore, it is important that both its desired and 
undesired effects be deeply evaluated. The goals of 
chemotherapy are to induce cytotoxicity with 
tolerable side effects.  
Results obtained in this study can corroborate the 
findings of literature, as RBC, hemoglobin, 
hematocrit, total protein, WBC, neutrophil count, 
urea, ALT, ALP, GGT and urinary density worsened 
during treatment (P ??????????????????????????
between those parameters and survival time was 
verified. 
The statistical results indicated that none of those 
evaluated parameters may be used as a prognostic 




Canine cutaneous lymphoma is associated with a 
poor prognosis due to its poor response to therapy, 
early relapse and short survival time, as confirmed in 
this study. 
The use of lomustine at 90 mg/m2 as a 
monotherapy in the treatment of canine cutaneous 
lymphoma showed moderate efficacy, leading to 
partial remissions in more than half of the dogs of this 
study; however, important deleterious effects were 
noted, especially anorexia, vomiting, diarrhea, 
myelosuppression, and liver and kidney toxicity, 
worsening the clinical presentation and prognosis of 
the affected animals. 
These results are relevant and highlight the 
importance of further studies to establish a better 
therapeutic approach and determine prognostic 
markers for canine cutaneous lymphoma. 
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